^
    Back
    Association details:
    Biomarker:BRCA1 mutation + BRCA2 mutation
    Cancer:Ovarian Cancer
    Drug:AiRuiYi (fluzoparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Chin J Cancer Res
    Title:

    Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors

    Published date:
    04/29/2020
    Excerpt:
    In patients with germline BC susceptibility gene mutation (gBRCA Mut) (11/43 OC; 2/16 BC), mPFS was 8.9 months for OC (range, 1.0-23.2; 95% CI, 1.0-16.8) and 14 and 28 months for BC (those two patients both also had somaticBRCA Mut)….Efficacy in patients with gBRCA1/2Mut gBRCA1/2Mut was tested in 43 patients with OC and 16 patients with BC; 11 in 43 OC (7 gBRCA1Mut, 2 gBRCA2Mut, 2 both gBRCA1/2Mut) and 2 in 16 BC (one gBRCA2Mut, one both gBRCA1/2Mut) had a gBRCAMut.
    DOI:
    10.21147/j.issn.1000-9604.2020.03.08